Dataciencia

Colección SciELO Chile

Induction of remission of idiopathic anaphylaxis with rituximab

Indexado

WoS	WOS:000343155700035
Scopus	SCOPUS_ID:84908126064

DOI

10.1016/J.JACI.2014.05.032

Año

2014

Tipo

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras

Revista

Revista	ISSN
Journal Of Allergy And Clinical Immunology	0091-6749

Métricas Externas

PlumX	Altmetric	Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Plumx: https://plumanalytics.com/learn/about-metrics/
Altmetric: https://www.altmetric.com/about-altmetrics/what-are-altmetrics/
Dimensions: https://www.dimensions.ai/why-dimensions/

Disciplinas de Investigación

WOS
Immunology
Allergy

Scopus
Sin Disciplinas

SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional

Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.

Autores - Afiliación

Ord.	Autor	Género	Institución - País
1	BORZUTZKY-SCHACHTER, ARTURO	Hombre	Pontificia Universidad Católica de Chile - Chile
2	MORALES-MATAMALA, Pamela S.	Mujer	Pontificia Universidad Católica de Chile - Chile
3	MEZZANO-ROBINSON, VERONICA	Mujer	Pontificia Universidad Católica de Chile - Chile
4	Nussbaum, Sofia	Mujer	Pontificia Universidad Católica de Chile - Chile
5	Burks, A. Wesley	-	UNIV N CAROLINA - Estados Unidos UNC School of Medicine - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento

Fuente
FONIS
Fondo Nacional de Desarrollo Científico y Tecnológico
Abbott Laboratories
Pfizer
Roche
Novartis Laboratories

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos

Agradecimiento
Disclosure of potential conflicts of interest: A. Borzutzky has been a speaker for Roche and Novartis Laboratories (Chile); has received research support from Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT grant nos. 1130615 and 1130387) (Chile) and FONIS (grant no. SA13I20173) (Chile); has received lecture fees from Roche Laboratories (Chile) and Pfizer (Chile); and has received travel support from Pfizer (Chile) and Abbott Laboratories (Chile). V. Mezzano has received lecture fees from Brystol-Myers Squibb and has received support for travel, accommodations, and meeting registration from Janssen. A. W. Burks is or has been on the board for Food Allergy Research and Education, the American Academy of Allergy, Asthma & Immunology, and the Food Allergy Initiative ; has received consultancy fees from Dynavax Technologies Corp , Genalyte , GLG Research , Perrigo Company , Regeneron Pharmaceuticals , Perosphere Inc , Dow AgroSciences , ExploraMed Development , McNeil Nutritionals , Merck , Nordic Biotech , Norvartis Pharma AG , Nutricia North American , Portola Pharaceuticals , Publicis Healthcare Communications Group , and Unilever ; has received research support from Hycor Biomedical ; has received lecture fees from Abbott Laboratories , the American College of Allergy , Asthma, and Immunology , and Mylan Speciality ; has received royalties from UpToDate; has received payment for development of educational presentations from Levine Children's Hospital and Oak Ridge Associated Universities ; and has stock/stock options in Allertein and MastCell Pharmaceuticals . The rest of the authors declare that they have no relevant conflicts of interest.

Agradecimiento

Disclosure of potential conflicts of interest: A. Borzutzky has been a speaker for Roche and Novartis Laboratories (Chile); has received research support from Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT grant nos. 1130615 and 1130387) (Chile) and FONIS (grant no. SA13I20173) (Chile); has received lecture fees from Roche Laboratories (Chile) and Pfizer (Chile); and has received travel support from Pfizer (Chile) and Abbott Laboratories (Chile). V. Mezzano has received lecture fees from Brystol-Myers Squibb and has received support for travel, accommodations, and meeting registration from Janssen. A. W. Burks is or has been on the board for Food Allergy Research and Education, the American Academy of Allergy, Asthma & Immunology, and the Food Allergy Initiative ; has received consultancy fees from Dynavax Technologies Corp , Genalyte , GLG Research , Perrigo Company , Regeneron Pharmaceuticals , Perosphere Inc , Dow AgroSciences , ExploraMed Development , McNeil Nutritionals , Merck , Nordic Biotech , Norvartis Pharma AG , Nutricia North American , Portola Pharaceuticals , Publicis Healthcare Communications Group , and Unilever ; has received research support from Hycor Biomedical ; has received lecture fees from Abbott Laboratories , the American College of Allergy , Asthma, and Immunology , and Mylan Speciality ; has received royalties from UpToDate; has received payment for development of educational presentations from Levine Children's Hospital and Oak Ridge Associated Universities ; and has stock/stock options in Allertein and MastCell Pharmaceuticals . The rest of the authors declare that they have no relevant conflicts of interest.